HighTower Advisors LLC Boosts Holdings in BioNTech SE Sponsored ADR $BNTX

Key Points

• HighTower Advisors LLC increased its stake in BioNTech SE by 46.2%, owning 16,077 shares valued at approximately $1.46 million.
• BioNTech reported a loss of ($1.60) earnings per share, missing the consensus estimate, but had a 102.6% increase in revenue compared to the same quarter last year.
• Wall Street analysts generally rate BioNTech as a "Moderate Buy," with an average target price of $135.80 per share.

HighTower Advisors LLC lifted its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 46.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,077 shares of the company's stock after purchasing an additional 5,079 shares during the period. HighTower Advisors LLC's holdings in BioNTech were worth $1,464,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of BNTX. Banque Cantonale Vaudoise acquired a new position in BioNTech in the first quarter valued at $36,000. Costello Asset Management INC acquired a new position in BioNTech in the first quarter valued at $91,000. Goodman Advisory Group LLC acquired a new position in BioNTech in the first quarter valued at $105,000. Whittier Trust Co. lifted its holdings in BioNTech by 3,846.2% in the first quarter. Whittier Trust Co. now owns 2,052 shares of the company's stock valued at $187,000 after buying an additional 2,000 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in BioNTech by 61.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock valued at $214,000 after buying an additional 713 shares during the period. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Stock Down 1.9%

BioNTech stock traded down $1.93 during midday trading on Friday, hitting $100.00. 505,405 shares of the stock were exchanged, compared to its average volume of 929,146. BioNTech SE Sponsored ADR has a 52-week low of $81.20 and a 52-week high of $131.49. The stock has a market capitalization of $24.04 billion, a price-to-earnings ratio of -62.50 and a beta of 1.23. The business's 50-day moving average price is $109.79 and its 200-day moving average price is $105.18. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). The company had revenue of $306.46 million during the quarter, compared to analysts' expectations of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm's revenue was up 102.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. On average, research analysts expect that BioNTech SE Sponsored ADR will post -3.88 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BNTX has been the topic of several recent analyst reports. Leerink Partners set a $112.00 target price on shares of BioNTech in a report on Monday, June 2nd. Wells Fargo & Company set a $150.00 price target on shares of BioNTech and gave the company an "overweight" rating in a research note on Tuesday, August 5th. Wall Street Zen raised shares of BioNTech from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Morgan Stanley lifted their price target on shares of BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. Finally, Citigroup reaffirmed a "buy" rating and issued a $140.00 price target (down from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Thirteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $135.80.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.